Ridgewood Investments LLC held its stake in shares of Chemed Corp. (NYSE:CHE) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,107 shares of the company’s stock at the end of the second quarter. Ridgewood Investments LLC’s holdings in Chemed Corp. were worth $226,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of the stock. BlackRock Inc. boosted its stake in shares of Chemed Corp. by 145,760.9% in the first quarter. BlackRock Inc. now owns 1,955,994 shares of the company’s stock worth $357,341,000 after buying an additional 1,954,653 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Chemed Corp. by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,795,773 shares of the company’s stock valued at $328,070,000 after buying an additional 125,018 shares during the period. State Street Corp boosted its stake in shares of Chemed Corp. by 9.1% in the first quarter. State Street Corp now owns 445,367 shares of the company’s stock valued at $81,370,000 after buying an additional 37,085 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in shares of Chemed Corp. during the first quarter valued at approximately $4,445,000. Finally, Neuberger Berman Group LLC boosted its stake in shares of Chemed Corp. by 2.2% in the first quarter. Neuberger Berman Group LLC now owns 1,060,403 shares of the company’s stock valued at $193,725,000 after buying an additional 23,306 shares during the period. Institutional investors and hedge funds own 97.78% of the company’s stock.
Shares of Chemed Corp. (NYSE CHE) opened at 191.88 on Monday. The firm has a 50-day moving average of $201.50 and a 200 day moving average of $191.93. The company has a market capitalization of $3.07 billion, a PE ratio of 47.60 and a beta of 1.14. Chemed Corp. has a 12 month low of $130.05 and a 12 month high of $216.01.
Chemed Corp. (NYSE:CHE) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.89 by $0.26. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. The business had revenue of $415.06 million for the quarter, compared to analyst estimates of $407.56 million. During the same quarter in the prior year, the firm posted $1.80 earnings per share. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. On average, equities research analysts expect that Chemed Corp. will post $8.20 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Monday, August 14th will be paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 0.58%. The ex-dividend date of this dividend is Thursday, August 10th. This is a positive change from Chemed Corp.’s previous quarterly dividend of $0.26. Chemed Corp.’s dividend payout ratio is 28.07%.
TRADEMARK VIOLATION WARNING: This report was published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://transcriptdaily.com/2017/08/14/chemed-corp-nyseche-position-maintained-by-ridgewood-investments-llc.html.
Several equities research analysts have commented on the stock. BidaskClub cut shares of Chemed Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Royal Bank Of Canada reiterated a “hold” rating and issued a $209.00 price target on shares of Chemed Corp. in a research report on Monday, July 31st. TheStreet cut shares of Chemed Corp. from a “b+” rating to a “c+” rating in a research report on Tuesday, July 25th. Zacks Investment Research upgraded shares of Chemed Corp. from a “hold” rating to a “buy” rating and set a $226.00 price target on the stock in a research report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. boosted their price target on shares of Chemed Corp. from $200.00 to $220.00 and gave the stock an “outperform” rating in a research report on Thursday, July 27th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $218.33.
In other news, Director George J. Walsh III purchased 1,000 shares of the business’s stock in a transaction dated Monday, June 26th. The shares were acquired at an average price of $204.56 per share, with a total value of $204,560.00. Following the completion of the purchase, the director now directly owns 7,908 shares of the company’s stock, valued at approximately $1,617,660.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Kevin J. Mcnamara sold 15,000 shares of the stock in a transaction dated Friday, July 28th. The shares were sold at an average price of $201.16, for a total value of $3,017,400.00. Following the completion of the transaction, the insider now directly owns 173,801 shares in the company, valued at approximately $34,961,809.16. The disclosure for this sale can be found here. Corporate insiders own 5.32% of the company’s stock.
About Chemed Corp.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corp. (NYSE:CHE).
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.